Advertisement

Topics

InDex secures FDA orphan-drug designation for cobitolimod

06:12 EDT 10 Aug 2017 | Pharmaceutical Business Review

InDex Pharmaceuticals has secured the orphan-drug designation for the drug candidate cobitolimod from the US Food and Drug Administration (FDA) for treatment of ulcerative colitis in pediatric patients.

Original Article: InDex secures FDA orphan-drug designation for cobitolimod

NEXT ARTICLE

More From BioPortfolio on "InDex secures FDA orphan-drug designation for cobitolimod"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...